Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines?-Reference-Cited by-同舟云学术

Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines?

Published:2012-06-20 Issue:18 Volume:30 Page:2179-2182
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Burstein Harold J.¹,Piccart-Gebhart Martine J.²,Perez Edith A.³,Hortobagyi Gabriel N.⁴,Wolmark Norman⁵,Albain Kathy S.⁶,Norton Larry⁷,Winer Eric P.¹,Hudis Clifford A.⁷

Affiliation:

1. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2. Institut Jules Bordet, Brussels, Belgium

3. Mayo Clinic, Jacksonville, FL

4. MD Anderson Cancer Center, Houston, TX

5. Allegheny General Hospital, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA

6. Loyola University Chicago Stritch School of Medicine, Maywood, IL

7. Memorial Sloan-Kettering Cancer Center, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.42.0695

Reference19 articles.

1. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

2. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

3. Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

4. Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

5. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decision Science Can Inform Clinical Trade-Offs Regarding Cardiotoxic Cancer Treatments;JNCI Cancer Spectrum;2021-06-24

2. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients;International Journal of Clinical Oncology;2019-02-27

3. Adjuvant Therapy for HER-2-Positive Early Breast Cancer;Breast Disease;2019

4. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review;Current Treatment Options in Oncology;2018-05-11

5. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer;Breast Cancer Research and Treatment;2017-07-14